Evidence mapPaperPMID 35618446Full record

Trial reportBMJ open diabetes research & care2022

Thrice daily consumption of a novel, premeal shot containing a low dose of whey protein increases time in euglycemia during 7 days of free-living in individuals with type 2 diabetes.

Kieran Smith, Guy S Taylor, Lise H Brunsgaard, Mark Walker, Kelly A Bowden Davies, Emma J Stevenson, Daniel J West

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in BMJ open diabetes research & care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Review
  10. Article
  11. Efficacy of Ma'aljobon Aftimouni (Contemporary clinical trials communications · 2025
    Article
  12. Review
  13. Manipulation of Post-Prandial Hyperglycaemia in Type 2 Diabetes: An Update for Practitioners.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024
    Review
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kieran SmithPopulation Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.ORCID 0000-0001-7275-4379
Guy S TaylorPopulation Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.ORCID 0000-0002-5207-1498
Lise H BrunsgaardHealth and Performance Nutrition, Arla Foods Ingredients Group P/S, Viby J, Denmark.
Mark WalkerBiosciences Institute, Newcastle University, Newcastle upon Tyne, UK.
Kelly A Bowden DaviesPopulation Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.
Emma J StevensonPopulation Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.
Daniel J WestPopulation Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK daniel.west@newcastle.ac.uk.ORCID 0000-0003-2246-4925

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDuring acute feeding trials, consuming a large dose of whey protein (WP) before meals improves postprandial glucose regulation in people with type 2 diabetes. It is unclear if the reported benefits of premeal WP supplementation are translatable to everyday care or are associated with clinically meaningful, real-world glycemic outcomes. This study examined the application of a novel, premeal shot containing a low dose of WP on parameters of free-living glycemic control in people with type 2 diabetes. RESEARCH DESIGN AND

methodsIn a randomized, placebo-controlled, single-blind crossover design, 18 insulin naive individuals with type 2 diabetes ((mean±SD) age, 50±6 years; HbA

resultsMealtime WP supplementation reduced the prevalence of daily hyperglycemia by 8%±19% (30%±25% vs 38%±28%, p<0.05), thereby enabling a 9%±19% (~2 hours/day) increase in the time spent in euglycemia (p<0.05). Mean 24-hour blood glucose concentrations were 0.6±1.2 mmol/L lower during WP compared with placebo (p<0.05). Similar improvements in glycemic control were observed during the waken period with premeal WP supplementation (p<0.05), whereas nocturnal glycemic control was unaffected (p>0.05). Supplemental compliance/acceptance was high (>98%), and no adverse events were reported.

conclusionsConsuming a novel premeal WP shot containing 15 g of protein before each main meal reduces the prevalence of daily hyperglycemia, thereby enabling a greater amount of time spent in euglycemic range per day over 7 days of free-living in people with type 2 diabetes. TRIAL REGISTRATION NUMBER: ISRCTN17563146; www.isrctn.com/ISRCTN17563146.

Indexed as

Diabetes Mellitus, Type 2HyperglycemiaAdultBlood GlucoseBlood Glucose Self-MonitoringCross-Over StudiesHumansMiddle AgedSingle-Blind MethodWhey ProteinsBlood GlucoseWhey ProteinsDiabetes Mellitus, Type 2

Identifiers

PMID35618446
PMCPMC9137348

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.